Objectives. The objectives of this study were to evaluate the therapeutic efficacy of CPH 82 in comparison with methotrexate (MTX ) in adult patients with early, active rheumatoid arthritis (RA) and to compare the tolerance and safety profiles of the two drugs.
CPH 82, a semi-synthetic podophyllotoxin glycoside compare the tolerance and the safety profiles of the two drugs. with anti-rheumatic properties, has been shown to be more effective than placebo in the treatment of established active rheumatoid arthritis (RA) [1, 2] . Other Materials and methods data suggest that it is as effective as sulphasalazine [3] and has a more rapid onset of action than auranofin
The trial was designed as a 24-week, double-blind, randomized study in which 10 centres participated with [4] . Korpela et al. [5] reported that CPH 82 was as effective as azathioprine in the treatment of RA with a total of 100 patients who were at least 18 yr of age. The patients were randomly assigned to treatment with amyloidosis and was also better tolerated. The aim of the present study was to extend our knowledge of the CPH 82 soft gelatin capsules, 300 mg daily, or MTX tablets, 10 mg weekly, the appropriate placebo form clinical efficacy and safety of CPH 82 by comparing it with methotrexate (MTX ), which has a wellalso being administered in all cases (double-dummy technique). The patients had to fulfil at least four of the documented clinical effect in established active RA [6 ] . The primary objective was to evaluate the therapeutic seven 1988 American Rheumatism Association (ARA) criteria for RA [7] and have a disease duration of less efficacy of CPH 82 in comparison with MTX in adult patients suffering from early, active RA and to determine than 2 yr. They were to display symptoms of active synovitis in at least four joints and have a C-reactive whether CPH 82 is at least as good as MTX in regard to clinical efficacy. The secondary objective was to protein (CRP) level of Á20 mg/l. Treatment with other disease-modifying antirheumatic drugs (DMARDs) in the 6-week period pre-drugs was also proscribed during the study. The patients tailed 95% confidence interval for the difference between the groups did not exceed 15% of the range of changes were allowed to take salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs), if necessary.
from baseline values. Patients who had been receiving a low and constant maintenance dose of systemic corticosteroids (not Results exceeding prednisolone 7.5 mg daily or the equivalent) could be admitted. During the study an increase in the Baseline data dose of systemic corticosteroid was not allowed.
The treatment groups should have been comparable as However, if a patient improved, a decrease was allowed.
a result of randomization. However, a significant differIntra-articular injections of corticosteroids were permitence in mean age between the treatment groups was ted in cases of pronounced synovitis in a single joint found. Demographic and clinical data at baseline are combined with functional impairment. However, if these given in Table 1 . injections were administered within 2 weeks prior to a clinical effect assessment, the patient had to be withTherapeutic efficacy drawn from the study.
All six primary variables (number of swollen joints, RAI, patient's pain score, patient's global score, HAQ Evaluations and CRP) showed a significant improvement in both For the evaluation of efficacy, the following outcome the CPH 82 and MTX groups during the 24 weeks variables were regarded as primary variables: number (P < 0.001). of swollen joints, number of tender joints ( Ritchie's For the number of swollen joints and RAI, the articular index; RAI ) [8] , patient's pain rating on a improvement was about 50%, while for HAQ and visual analogue scale, patient's global score on a visual patient's global score, the improvement was about 40%, analogue scale, Health Assessment Questionnaire the differences between the treatment groups being non-(HAQ) index [9, 10] and serum CRP. The number of significant. The improvement in patient's pain ratings intra-articular corticosteroid injections served as a secwas 37% in the CPH 82 group and 51% in the MTX ondary effect variable. The physician's global rating of group, which represented a significant difference between disease activity and the erythrocyte sedimentation rate the groups (P = 0.036). The improvement in CRP was ( ESR) were also analysed. In addition to what was 33% in the CPH 82 group and 66% in the MTX group, prescribed by the original study protocol, efficacy was which was also a significant difference (P = 0.001; also assessed according to the European League Against Table 2 ).
Rheumatism ( EULAR) response criteria [11] and the
For three of the six primary variables (number of American College of Rheumatology (ACR) response swollen joints, the patient's global assessment and criteria [12] . HAQ), the upper 90% confidence limit values were For the evaluation of safety, continuous adverse event within 15% of the equivalence limit. In the remaining monitoring was performed as well as biochemical montwo clinical variables (RAI and patient's pain score), itoring, including variables reflecting bone marrow functhis confidence interval was within the 20% equivalence tion, liver function and renal function. If a serum value limit. For CRP, however, the upper 90% confidence of levels of aminotransferases (ASAT, ALAT ) or creatiinterval was outside the 20% equivalence limit, indicating nine exceeded twice the upper limit of the respective that the acute-phase response in MTX-treated patients normal range, this was considered to be a treatment was better than that in CPH 82-treated patients. failure and the patient was withdrawn from the study.
In addition to the primary variables, the physician's global ratings and the ESR were also assessed. The Statistical analysis physician's global ratings improved by 48% in the CPH Treatment groups were compared using the chi-squared 82 group and by 57% in the MTX group, a difference test for binary variables, Wilcoxon's rank-sum test for which was not significant (P = 0.1). Consistent with the ordered categorical variables and the t-test for continu-CRP response, ESR decreased significantly in both ous variables. All the statistical tests were carried out at groups, by 22% in the CPH 82 group (P = 0.0097) and the 5% level. Efficacy was assessed in terms of change from baseline values for the outcome variables. In cases between treatment groups were given as 95% confidence by 51% in the MTX group (P = 0.0001), amounting to In the CPH 82 group, two adverse events led to a treatment failure: one case of pruritus and one case of a significant difference (P = 0.0005).
The analysis of the individual ACR and EULAR periorbital oedema. In addition, one patient had a transient facial oedema and one patient had transient responses was made using the values after 24 weeks or the last available values (endpoint analysis). Twentymild anaemia and leucopenia. No case of liver toxicity was observed in the CPH 82 group. In the MTX nine patients in the CPH 82 group and 32 patients in the MTX group reached ACR20 response criteria.
group, 14 adverse events led to treatment failure: one progressive leucopenia (minimum 2.8 × 109/l ), one ACR50 response criteria were reached by 13 CPH 82 patients and 20 MTX patients, the differences between progressive leucopenia with thrombocytopenia (minimum 2.6 × 109/l and 122 × 109/l, respectively), 11 groups in both categories (ACR20 and ACR50) being non-significant, P = 0.539 and P = 0.137, respectively. increased liver enzymes, one pruritus and rash. There was a significant increase in mean serum levels of ASAT According to the EULAR criteria, 23 patients in the CPH 82 group (46%) and 24 patients in the MTX group and ALAT in the patients treated with MTX. (48%) reached the criteria for moderate response. The corresponding figures for good response were 15 (30%) Discussion and 19 (38%), respectively. There was no significant difference between the groups in EULAR response (P = MTX has a well-documented therapeutic effect in the treatment of RA, and rheumatologists in many countries 0.22). Twelve (24%) of the CPH 82 patients and seven (14%) of the MTX patients failed, being non-responders have long experience of its use. However, a considerable number of patients do not tolerate long-term treatment according to the EULAR definition.
Responses to both drugs were parallel in time and with MTX, due to toxicity to the liver, the lungs, the haemopoietic system and other organs. Moreover, some near the maximum after 12 weeks of treatment. This improvement persisted throughout the 24 weeks of the patients derive insufficient benefit from the drug. Thus, there is obviously a need for alternative drugs, and the study. Five patients in the CPH 82 group and one in the MTX group terminated the study prematurely due purpose of the present study was to investigate whether CPH 82 might be such an alternative, in terms of efficacy to lack of efficacy. There were no significant group differences in the number of patients who terminated and of safety. The dose of MTX in this study has been under prematurely due to lack of response, the number of intra-articular corticosteroid injections given or the debate. Some rheumatologists would commence with 7.5 mg/week and increase the dose if needed, while number of patients on systemic corticosteroids, NSAIDs or analgesics.
others have claimed that the mean dose of MTX currently used is well over 17.5 mg/week. However, unpubSafety lished data from the Swedish RA register show that the mean dose of MTX given to RA patients in Sweden In total, 52 adverse events in the CPH 82 group and 73 in the MTX group were assessed by the investigators as within the first 12 months of disease is just below 10 mg/week (S. Lindblad, personal communication). having a possible association with the study drug. In the CPH 82 group, one case each of nausea and diaTherapeutic efficacy rrhoea and in the MTX group, two cases of leucopenia, three elevated liver enzymes and one each of nausea, Both drugs yielded a significant improvement in all six primary effect variables, and for three of the variables, diarrhoea, hearing impairment and hyperhidrosis were classified as severe adverse events ( Table 3) . Gastrothe response to CPH 82 was at least as good as that of MTX, according to the equivalence criteria used. The intestinal manifestations were the most common adverse events, being characterized by similar frequency, sympresults suggest that the clinical effects of CPH 82 300 mg/day and MTX 10 mg/week are essentially the tomatology and severity in both treatment groups. No patient terminated the study prematurely due to same. Despite the similarity of the two drugs in their effect on clinical variables, the significant difference in gastrointestinal side-effects. Gastrointestinal system disorders  12  5  2  19  15  8  2  25  Liver and biliary system disorders  0  0  0  0  8  0  3  11/13a  Haemopoietic system disorders  4  0  0  4  1  2  2  5  Other different system disorders  19  5  0  24  24  8  2  34  Total  35  10  2  47  48  18  9  75/77a aTwo cases were not rated for the severity of the hepatic function disorder.
their effect on acute-phase response suggests that they prolonged treatment. However, some of the premature withdrawals would probably not have been necessary if may have different modes of action. Further light may be shed on this matter during the open prolongation of the current guidelines for monitoring liver toxicity in patients on MTX had been applied in the present the study over 74 weeks.
study [14] .
Safety
The clinical effect of CPH 82 in this trial was comparable with that of MTX 10 mg/week. Both drugs reduced The present findings suggest that the gastrointestinal side-effects of CPH 82 reported in earlier studies have acute-phase reactants, MTX more effectively than CPH 82. MTX was associated both with a greater overall been largely overcome by the introduction of the entericcoated capsules used in this trial. For both drugs, these prevalence of adverse events and with potentially severe side-effects involving the liver and haemopoietic organs. side-effects can be reduced or even eliminated by reducing the daily dose. In the case of MTX, folic acid However, some of the side-effects of MTX, including hepatotoxicity, might have been reduced if folic acid supplementation may also be beneficial.
In the present study, one case of transient facial supplementation had been used. An important advantage of CPH 82 over MTX is the lack of contraindications oedema was reported, which disappeared despite continued treatment. Another patient was withdrawn from in terms of previous disease of haemopoietic organs, liver or lungs. CPH 82 would, therefore, seem to be a the study due to periorbital oedema. The reason for oedema in these two patients and in earlier reported useful alternative to MTX, particularly in patients who do not tolerate MTX well or where pre-existing disease cases is not clear. The swelling has invariably disappeared following discontinuation of the treatment. As of the liver, lungs or haemopoietic organs constitutes a contraindication for the use of MTX. in some of the earlier cases of oedema, the two patients in this study had been taking systemic corticosteroids and/or injections of corticosteroids, which may have
